SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SANGUINE CORP. (SGNC)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jim B who wrote (1659)6/24/1998 1:21:00 AM
From: chirodoc  Read Replies (1) of 5402
 
YOU GOTTA READ THIS!!!!
THE JAPANESE USED THIS (OLD VERSION--1981) ON 185 PATIENTS IN PHASE II/III TRIALS!!!!!
--WITH NO SIDE EFFECTS!!!!

....... All other hematological and biochemical parameters measured in blood, serum and urine remained within normal ranges.

Prog Clin Biol Res 1981;55:609-628

Development of a perfluorochemical whole blood substitute (Fluosol-DA, 20%)--an overview of clinical studies with 185 patients.

Suyama T, Yokoyama K, Naito R

Fluosol-DA, 20%, a perfluorochemical whole blood substitute, was infused during Phase II and Phase III clinical trials at 24 medical institutions in Japan to 185 patients for replacement of blood lost during surgery or for improvement of cerebral circulation. Its active ingredients (perfluorodecalin, perfluorotripropylamine, hydroxyethyl starch and Krebs-Ringer bicarbonate solution) give this biologically inert emulsion not only plasma-expanding properties but also a high oxygen-carrying capacity (7.2 vol.% at 37 degrees C; the oxygen carrying capacity of red blood cells is 17 to 20 vol.%). Doses given to the patients ranged from 6 to 25 ml/kg body weight. With regard to arterial blood oxygen tension, arterial blood oxygen content, blood oxygen transport, oxygen consumption, and acid-base balance, beneficial effects were generally observed after infusion of the emulsion following blood loss especially when the fractional concentration of oxygen in inspired gas (FiO2) was kept higher than 0.5. The emulsion also manifested beneficial plasma-expander effects on hemodynamics (blood pressure, pulse rate, and central venous pressure). In no case was there any anaphylactoid or other untoward reaction observed or reported during or after infusion of the emulsion. Although a slight prolongation of bleeding time (Duke) was found, the surgeons never experienced and hemorrhagic tendencies during or after their operations. Slight and transient elevations of SGOT were found but SGPT and alkaline phosphatase levels remained normal. All other hematological and biochemical parameters measured in blood, serum and urine remained within normal ranges.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext